Clinical implications of neuroendocrine differentiation in prostate cancer (Q36639877)

15 August 2017

1 reference

title

Clinical implications of neuroendocrine differentiation in prostate cancer (English)

1 reference

15 August 2017

1 reference

Nelson EC

1

1 reference

15 August 2017

Cambio AJ

2

1 reference

15 August 2017

Yang JC

3

1 reference

15 August 2017

Ok JH

4

1 reference

15 August 2017

Lara PN Jr

5

1 reference

15 August 2017

Evans CP

6

1 reference

15 August 2017

publication date

31 October 2006

1 reference

Prostate Cancer and Prostatic Diseases

15 August 2017

published in

1 reference

15 August 2017

volume

10

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

6-14

1 reference

15 August 2017

cites work

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Neuroendocrine cells in tumour growth of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Autocrine and paracrine signaling through neuropeptide receptors in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Neurogenic origin of human prostate endocrine cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Regulation of tyrosine kinase cascades by G-protein-coupled receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

In vitro regulation of pericellular proteolysis in prostatic tumor cells treated with bombesin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells .

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Neuroendocrine differentiation in prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Circulating chromogranin a and hormone refractory prostate cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Ectopic expression of the serotonin 1c receptor and the triggering of malignant transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Angiogenesis is not mediated by prostate cancer neuropeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Neuroendocrine pathogenesis in adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Prostatic hyperplasia: an unknown feature of acromegaly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

The development of androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Regulation of prostatic growth and function by peptide growth factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Prostatic cell lineage markers: emergence of BCL2+ cells of human prostate cancer xenograft LuCaP 23 following castration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Bombesin stimulates the motility of human prostate-carcinoma cells through tyrosine phosphorylation of focal adhesion kinase and of integrin-associated proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

In situ hybridization for gastrin-releasing peptide receptor (GRP receptor) expression in prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Somatostatin analogues and estrogens in the treatment of androgen ablation refractory prostate adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Suramin's development: what did we learn?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Neuropeptides bombesin and calcitonin inhibit apoptosis-related elemental changes in prostate carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Mechanisms of vascular growth-promoting effects of neuropeptide Y: role of its inducible receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Proadrenomedullin NH2-terminal 20 peptide is a potent angiogenic factor, and its inhibition results in reduction of tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Proadrenomedullin N-terminal 20 peptide (PAMP) elevates blood glucose levels via bombesin receptor in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Expression of serotonin receptors 2B and 4 in human prostate cancer tissue and effects of their antagonists on prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Vascular endothelial growth factor and signaling in the prostate: more than angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

7 January 2021

Do neuroendocrine cells in human prostate cancer express androgen receptor?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

7 January 2021

Characterization of intracellular calcium mobilization by bombesin-related neuropeptides in PC-3 human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

7 January 2021

Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

7 January 2021

Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

7 January 2021

Immunohistochemical localization of parathyroid hormone-related protein in prostatic intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

7 January 2021

Neuroendocrine differentiation in prostatic intraepithelial neoplasia and adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

7 January 2021

Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

7 January 2021

Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

7 January 2021

The pattern of serum markers in patients with androgen-independent adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

7 January 2021

Clinical significance of elevation in neuroendocrine factors and interleukin-6 in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

7 January 2021

Bombesin stimulates growth of human prostatic cancer cells in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

7 January 2021

Parathyroid hormone-related protein is expressed by prostatic neuroendocrine cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

7 January 2021

Correlation between neovascularisation and neuroendocrine differentiation in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

7 January 2021

EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

7 January 2021

Neuroendocrine cell differentiation in the CWR22 human prostate cancer xenograft: association with tumor cell proliferation prior to recurrence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

7 January 2021

Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

7 January 2021

Quantitative immunohistochemical analysis of insulin-like growth factor binding protein-3 in human prostatic adenocarcinoma: a prognostic study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

7 January 2021

Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

7 January 2021

Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

7 January 2021

Neuroendocrine differentiation in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

7 January 2021

The Prognostic Value of Neuroendocrine Differentiation in Adenocarcinoma of the Prostate in Relation to Progression of Disease After Endocrine Therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500922

7 January 2021

Identifiers

DOI

10.1038/SJ.PCAN.4500922

1 reference

15 August 2017

1 reference